Overview

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
Phase:
Phase 2
Details
Lead Sponsor:
October 6 University
Collaborator:
Beni-Suef University
Treatments:
Antihypertensive Agents
Hypolipidemic Agents